Gilead grants Japan Tobacco exclusive rights to develop and commercialize cobicistat in Japan

Gilead Sciences Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$31,716.8m on 12/30/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Japan Tobacco Inc.

Japan / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced